Literature DB >> 28947107

Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.

Haifa Shen1, Tong Sun2, Hanh H Hoang2, Jana S Burchfield2, Gillian F Hamilton2, Elizabeth A Mittendorf3, Mauro Ferrari4.   

Abstract

Cancer immunotherapy has become arguably the most promising advancement in cancer research and therapy in recent years. The efficacy of cancer immunotherapy is critically dependent on specific physiological and physical processes - collectively referred to as transport barriers - including the activation of T cells by antigen presenting cells, T cells migration to and penetration into the tumor microenvironment, and movement of nutrients and other immune cells through the tumor microenvironment. Nanotechnology-based approaches have great potential to help overcome these transport barriers. In this review, we discuss the ways that nanotechnology is being leveraged to improve the efficacy and potency of various cancer immunotherapies.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer immunotherapy; Nanotechnology; Tumor microenvironment; Tumor-infiltrating lymphocytes

Mesh:

Year:  2017        PMID: 28947107      PMCID: PMC5705528          DOI: 10.1016/j.smim.2017.09.002

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  123 in total

1.  Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics.

Authors:  Walter Wolf; Cary A Presant
Journal:  Clin Pharmacol Ther       Date:  2004-11       Impact factor: 6.875

2.  Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Authors:  Karlo Perica; Joan Glick Bieler; Christian Schütz; Juan Carlos Varela; Jacqueline Douglass; Andrew Skora; Yen Ling Chiu; Mathias Oelke; Kenneth Kinzler; Shibin Zhou; Bert Vogelstein; Jonathan P Schneck
Journal:  ACS Nano       Date:  2015-07-14       Impact factor: 15.881

Review 3.  Chimeric antigen receptor modified T cell therapy for B cell malignancies.

Authors:  Cameron J Turtle
Journal:  Int J Hematol       Date:  2013-12-14       Impact factor: 2.490

4.  Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix.

Authors:  Mathumai Kanapathipillai; Akiko Mammoto; Tadanori Mammoto; Joo H Kang; Elisabeth Jiang; Kaustabh Ghosh; Netanel Korin; Ashley Gibbs; Robert Mannix; Donald E Ingber
Journal:  Nano Lett       Date:  2012-05-10       Impact factor: 11.189

5.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy.

Authors:  Hengfeng Yuan; Wen Jiang; Christina A von Roemeling; Yaqing Qie; Xiujie Liu; Yuanxin Chen; Yifan Wang; Robert E Wharen; Kyuson Yun; Guojun Bu; Keith L Knutson; Betty Y S Kim
Journal:  Nat Nanotechnol       Date:  2017-05-01       Impact factor: 39.213

Review 7.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

Authors:  Tao Dao; Dmitry Pankov; Andrew Scott; Tatyana Korontsvit; Victoriya Zakhaleva; Yiyang Xu; Jingyi Xiang; Su Yan; Manuel Direito de Morais Guerreiro; Nicholas Veomett; Leonid Dubrovsky; Michael Curcio; Ekaterina Doubrovina; Vladimir Ponomarev; Cheng Liu; Richard J O'Reilly; David A Scheinberg
Journal:  Nat Biotechnol       Date:  2015-09-21       Impact factor: 54.908

9.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions.

Authors:  Alessandro Parodi; Nicoletta Quattrocchi; Anne L van de Ven; Ciro Chiappini; Michael Evangelopoulos; Jonathan O Martinez; Brandon S Brown; Sm Z Khaled; Iman K Yazdi; Maria Vittoria Enzo; Lucas Isenhart; Mauro Ferrari; Ennio Tasciotti
Journal:  Nat Nanotechnol       Date:  2012-12-16       Impact factor: 39.213

10.  Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.

Authors:  Joanna Kopecka; Stefania Porto; Sara Lusa; Elena Gazzano; Giuseppina Salzano; Martha Leonor Pinzòn-Daza; Antonio Giordano; Vincenzo Desiderio; Dario Ghigo; Giuseppe De Rosa; Michele Caraglia; Chiara Riganti
Journal:  Oncotarget       Date:  2016-04-12
View more
  8 in total

1.  Clinical Cancer Nanomedicine.

Authors:  Joy Wolfram; Mauro Ferrari
Journal:  Nano Today       Date:  2019-03-06       Impact factor: 20.722

Review 2.  Tumor targeting via EPR: Strategies to enhance patient responses.

Authors:  Susanne K Golombek; Jan-Niklas May; Benjamin Theek; Lia Appold; Natascha Drude; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2018-07-19       Impact factor: 15.470

Review 3.  Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes.

Authors:  Bruna Corradetti; Simone Pisano; Robert Steven Conlan; Mauro Ferrari
Journal:  J Pharmacol Exp Ther       Date:  2019-02-08       Impact factor: 4.030

Review 4.  Recent advances on smart glycoconjugate vaccines in infections and cancer.

Authors:  Marko Anderluh; Francesco Berti; Anna Bzducha-Wróbel; Fabrizio Chiodo; Cinzia Colombo; Federica Compostella; Katarzyna Durlik; Xhenti Ferhati; Rikard Holmdahl; Dragana Jovanovic; Wieslaw Kaca; Luigi Lay; Milena Marinovic-Cincovic; Marco Marradi; Musa Ozil; Laura Polito; Josè Juan Reina; Celso A Reis; Robert Sackstein; Alba Silipo; Urban Švajger; Ondřej Vaněk; Fumiichiro Yamamoto; Barbara Richichi; Sandra J van Vliet
Journal:  FEBS J       Date:  2021-06-01       Impact factor: 5.622

5.  ITGB1-DT/ARNTL2 axis may be a novel biomarker in lung adenocarcinoma: a bioinformatics analysis and experimental validation.

Authors:  Bai-Quan Qiu; Xia-Hui Lin; Song-Qing Lai; Feng Lu; Kun Lin; Xiang Long; Shu-Qiang Zhu; Hua-Xi Zou; Jian-Jun Xu; Ji-Chun Liu; Yong-Bing Wu
Journal:  Cancer Cell Int       Date:  2021-12-14       Impact factor: 5.722

6.  Expression profile and prognostic values of Chromobox family members in human glioblastoma.

Authors:  Juanni Li; Zhijie Xu; Lei Zhou; Kuan Hu
Journal:  Aging (Albany NY)       Date:  2022-02-24       Impact factor: 5.682

7.  LINC00511/hsa-miR-573 axis-mediated high expression of Gasdermin C associates with dismal prognosis and tumor immune infiltration of breast cancer.

Authors:  Kai Sun; Jing-Zhang Li; Zhan-Xiong Luo; Ri-Xin Chen
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

Review 8.  Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck.

Authors:  Qiang Xu; Meiyu Fang; Jing Zhu; Haoru Dong; Jun Cao; Lin Yan; Fransisca Leonard; Felix Oppel; Holger Sudhoff; Andreas M Kaufmann; Andreas E Albers; Xu Qian
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.